Aligos therapeutics presents positive clinical data at apasl 2024 from alg-055009 and alg-000184 phase 1 studies

South san francisco, calif., march 27, 2024 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs, “aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced three oral presentations and one poster presentation at the 33rd annual meeting of the asian pacific association for the study of the liver (apasl) 2024, being held march 27-31, 2024 in kyoto, japan.
ALGS Ratings Summary
ALGS Quant Ranking